AC Immune Ltd
$ 2.25
-6.25%
05 Jun - close price
- Market Cap 228,991,000 USD
- Current Price $ 2.25
- High / Low $ 2.46 / 2.21
- Stock P/E N/A
- Book Value 0.41
- EPS -0.84
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -1.05 %
- 52 Week High 4.00
- 52 Week Low 1.65
About
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.
Analyst Target Price
$8.83
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-13 | 2025-11-04 | 2025-08-05 | 2025-04-30 | 2025-03-13 | 2024-11-05 | 2024-08-06 | 2024-05-13 | 2024-03-14 | 2023-11-03 | 2023-08-04 |
| Reported EPS | -0.15 | -0.1401 | -0.16 | -0.21 | -0.19 | -0.16 | 0.06 | -0.23 | -0.18 | -0.05 | -0.18 | -0.2 |
| Estimated EPS | -0.14 | -0.1566 | -0.19 | -0.1742 | -0.207 | -0.1903 | -0.23 | 0.27 | -0.14 | -0.11 | 0.03 | -0.19 |
| Surprise | -0.01 | 0.0165 | 0.03 | -0.0358 | 0.017 | 0.0303 | 0.29 | -0.5 | -0.04 | 0.06 | -0.21 | -0.01 |
| Surprise Percentage | -7.1429% | 10.5364% | 15.7895% | -20.5511% | 8.2126% | 15.9222% | 126.087% | -185.1852% | -28.5714% | 54.5455% | -700% | -5.2632% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACIU
2026-05-28 18:08:53
AC Immune SA (ACIU) is currently considered in the "Fair zone" based on its forward PS ratio of 2.49 compared to its five-year average. While its current P/B ratio and Forward FCF yield show significant changes compared to historical averages, the company's P/S ratio of 2.41 is considerably below the competitor average but deemed unsustainable given its 13.03% revenue growth. The article also provides current P/B, FCF Yield, Forward P/E, and Forward P/S ratios for ACIU as of May 29, 2026.
2026-05-22 18:08:53
AC Immune SA announced new Phase 1 data showing increased brain uptake of its TDP-43 PET tracer ACI-19626 in patients with amyotrophic lateral sclerosis (ALS). The data, presented at the 2026 TDP43 Summit, indicate higher tracer uptake in key brain regions affected by TDP-43 pathology in ALS patients compared to healthy controls. This further supports ACI-19626's potential for early diagnosis and precision medicine approaches in various neurodegenerative diseases, including ALS and frontotemporal dementia (FTD).
2026-05-22 11:09:55
AC Immune SA announced new Phase 1 data showing its PET tracer, ACI-19626, has increased uptake in the brains of ALS patients, thus indicating its potential to detect pathological TDP-43. This tracer could allow for earlier diagnosis and intervention in neurodegenerative diseases. The data also confirmed the tracer's safety, tolerability, and suitable pharmacokinetic profile.
2026-05-22 11:09:21
AC Immune SA announced new Phase 1 data showing its TDP-43 PET tracer, ACI-19626, detects higher uptake in the brains of patients with amyotrophic lateral sclerosis (ALS) compared to healthy controls. The data, presented at the 2026 TDP43 Summit, support ACI-19626's potential for early diagnosis and intervention in various neurodegenerative diseases, including ALS and frontotemporal dementia (FTD). The ongoing trial also confirms the tracer's good safety and tolerability profile, suitable for human brain imaging.
2026-05-22 11:09:21
AC Immune SA announced new preliminary Phase 1 data for its TDP-43 PET tracer, ACI-19626, revealing enhanced uptake in the brains of ALS patients. This suggests the tracer's potential for early diagnosis of neurodegenerative diseases by effectively detecting TDP-43 pathology in key brain regions like the brain stem and precentral gyrus. The tracer also demonstrated good safety and tolerability, supporting its use in human brain imaging and for analyzing TDP-43-targeting therapies.
2026-05-22 11:09:21
AC Immune (NASDAQ: ACIU) announced new preliminary Phase 1 data showing its TDP-43 PET tracer ACI-19626 had significantly higher uptake in key brain regions of ALS patients compared to healthy controls. This tracer, which previously showed efficacy in frontotemporal dementia (FTD), is demonstrating potential for early diagnosis and precision medicine approaches in TDP-43 proteinopathies. The data, presented at the 2026 TDP43 Summit, indicates good safety, tolerability, and rapid brain uptake, supporting its use for human brain imaging.
